Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 6 recruiting now small index

Upper Extremity Paresis clinical trials

6 of 8 indexed Upper Extremity Paresis trials are currently recruiting.

Corpus placement: #2,176 of 28,707 conditions by registered trial count.

8 US clinical trials · 6 currently recruiting · #2,176 of 28,707 conditions by registered trial count

Upper Extremity Paresis: 8 US clinical trials tracked, 6 recruiting.

Upper Extremity Paresis is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. The most active sponsor is Baylor Research Institute, running 2 of these trials.

Enrollment posture brief

Registry condition upper-extremity-paresis

OPEN 6 | RECR 75% | LATE 0 | EARLY 0 | RANK #2176 | SPON 2

Nearest open-share peer: Adolescent Idiopathic Scoliosis (75% recruiting · 8 trials)

Activity, Motor75%Upper Extremity Paresis (thi…75%Achalasia50%Abdominal Cancer25%Acne Scars - Mixed Atrophic 25%
Open-enrollment share among volume-matched conditions near Upper Extremity Paresis

Upper Extremity Paresis lists 6 open slots (75% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Upper Extremity Paresis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Upper Extremity Paresis is recruiting above its size-band peers.

    6 of 8 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Upper Extremity Paresis research.

    Baylor Research Institute accounts for 2 of 8 trials (25%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Most Upper Extremity Paresis trials plan to enrol fewer than 100 people.

    Median target enrolment is 25 among the 8 trials that report a genuine target (sentinel values excluded). 7 of those (87.5%) plan for fewer than 100 participants.

  4. Upper Extremity Paresis research is mostly interventional.

    8 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase Distribution

Phase data not available

Named interventions

Most-linked intervention names on Upper Extremity Paresis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Vagus Nerve Stimulation Device
2 trials
Active Vagus Nerve Stimulation Device
2 trials
Somatosensory Electrical Stimulation Device
1 trials
Rehabilitation Other
1 trials
CCFES with Occupational Therapy Behavioral
1 trials
Sham tDCS plus CCFES Device
1 trials
Active unconventional tDCS montage plus CCFES Device
1 trials
Active conventional tDCS montage plus CCFES Device
1 trials

US sites by state

Facility locations filed on Upper Extremity Paresis trials. A trial with sites in several states counts in each.

Texas 3 trials
Ohio 2 trials
Alabama 2 trials
South Carolina 1 trials
Rhode Island 1 trials
Pennsylvania 1 trials
New York 1 trials
Minnesota 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Upper Extremity Paresis page

8 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Upper Extremity Paresis condition card totals 8 registered trials; most-linked intervention Placebo Vagus Nerve Stimulation; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.